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India has over a century old tradition of development and production of vaccines. The Government rightly 
adopted self-sufficiency in vaccine production and self-reliance in vaccine technology as its policy objectives in 
1986. However, in the absence of a full-fledged vaccine policy, there have been concerns related to demand and 
supply, manufacture vs. import, role of public and private sectors, choice of vaccines, new and combination 
vaccines, universal vs. selective vaccination, routine immunization vs. special drives, cost-benefit aspects, 
regulatory issues, logistics etc. The need for a comprehensive and evidence based vaccine policy that enables 
informed decisions on all these aspects from the public health point of view brought together doctors, scientists, 
policy analysts, lawyers and civil society representatives to formulate this policy paper for the consideration of 
the Government. This paper evolved out of the first ever ICMR-NISTADS national brainstorming workshop 
on vaccine policy held during 4-5 June, 2009 in New Delhi, and subsequent discussions over email for several 
weeks, before being adopted unanimously in the present form.
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*Based on deliberations of a workshop on vaccine policy held during 4-5 June, 2009 in New Delhi.
Policy Document
Introduction
 Vaccines are very useful as preventive medicine 
in public health to reduce morbidity and mortality 
due to communicable diseases, though they are not a 
substitute to safe drinking water, sanitation, nutrition 
and environmental health in the long run. 
Preamble 
 Vaccine R&D and production are areas of modern 
scientific endeavours in which India was among 
the leaders in the world, well over a century ago1. 
Independent India continued to rely on public sector 
vaccine production and readily adopted the policies 
of World Health Organization (WHO) and United 
Nations Children’s Fund (UNICEF) regarding mass 
immunization1. A policy objective of achieving self-
sufficiency in vaccine production and self-reliance in 
vaccine technology was formally adopted in 1986, with 
new public sector vaccine production units established 
to meet the demand-supply gaps in vaccines and for 
export2. However, over the years, many vaccine Public 
Sector Units (PSUs) have either been closed down 
or have stopped vaccine production1,3. Even though 
many private sector vaccine units sprang up during 
this period, often drawing directly or indirectly from 
the public sector resources, (such as raw materials, 
expertise, manpower and finances) vaccine production 
remained erratic and demand-supply gaps continue 
till date3,4. This is particularly true for most of the 
vaccines identified as essential for the various national 
programmes, while the market is flooded with a host 
of new vaccines and combination vaccines that are 
not a part of any national programme5. Thus, there is 
a growing mismatch between the stated policy of self-
reliance and self-sufficiency and the actual situation 
emerging on the ground that remains unaddressed.
Vaccine types and programmes
 From a policy perspective, there are many types of 
vaccines. Among the national programmes, the most 
important is the Universal Immunization Programme 
(UIP) for children, which includes 6 vaccines: BCG, 
DPT, polio, measles, DT and TT. These six vaccines 
are also known as the primary vaccines and universal 
immunization is also known as Routine Immunization 
(RI)6. Of these 6, polio vaccine receives a special 
emphasis as a part of the WHO global drive to eradicate 
polio7. Public sector manufacturing capacities exist 
for all these vaccines, though the closure of many 
PSUs over the last several decades and the suspension 
of three major PSUs in 2008 have affected their 
availability and affordability8. Then, there are the so-
called secondary vaccines for Selective Immunization 
(SI) against yellow fever, Japanese encephalitis, 
hepatitis B, typhoid, cholera, etc., required for specific 
risk groups or age groups or special situations across 
the whole country or selected states/regions. Most 
of these primary and secondary vaccines, required 
in bulk quantities by the Government agencies are 
often in short supply, perhaps with the exception of 
hepatitis B vaccine, and public sector units are not 
currently manufacturing them, though it is feasible in 
most cases. Therefore, this requirement is currently 
being met by the indigenous private sector or through 
imports. Furthermore, many of the therapeutic 
vaccines and antisera required in large quantities by 
the Government are made in the public sector. These 
include the anti-tetanus serum, diphtheria toxoid, anti-
snake venom, anti-rabies vaccine, animal husbandry 
vaccines etc. The public sector often maintains stocks 
of some of these vaccines/antisera beyond the normal 
usage levels to meet contingencies, a practice adding 
to the overall expenditure. In contrast, the vaccines 
abundantly available in the market are typically newer 
ones manufactured by the private sector/ multinational 
companies, against mumps, rubella, pneumococcal and 
meningococcal disease, rotavirus, influenza, human 
papilloma virus, newer typhoid vaccines, acellular 
pertussis vaccine, etc4.
 Many of the newer vaccines are quite expensive, 
especially since they are sold as combination vaccines. 
Virtually every combination vaccine combines the new 
vaccines (non-UIP) with at least one UIP vaccine5, 
such as DPT or measles, making it more difficult for 
public health agencies to deal with universal (RI) and 
non-universal vaccines (SI) as distinct categories for 
purchase and immunization.  Several more new vaccines 
are being developed world over9 that are entering the 
market every year (www.immunize.org). Even though 
none of the new vaccines (except hepatitis-B) is 
currently a part of any of the Government programmes, 
many of them are in widespread use, as private doctors 
often prescribe them and people purchase. There 
are frequent demands from the industry, medical 
associations and some international organizations and 
aid agencies that the newer vaccines be included into 
the national programmes10,11. Therefore, a major policy 
question for the government is: How many vaccines 
are to be included under any government (national/
state) programme to adequately fulfill its public health 
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commitments to the nation? A related policy question 
is: Should any (and how many) vaccines be left for 
voluntary vaccination by individuals, even under 
prescription, especially considering the difficulties 
in regulating irrational prescriptions12? What should 
be the norms to determine the necessity, suitability, 
safety, efficacy, accessibility and affordability of a 
vaccine at the individual level? Similarly, how should 
the government maximize the coverage potential 
and sustainability of a vaccination programme at the 
national level?
Budget allocation for vaccines
 The Government of India currently spends over 
Rs. 200 crores annually on the procurement of the 
6 UIP vaccines alone13 (excluding the Pulse Polio 
Immunization Programme). However, it manages to 
immunize only about half of over 26 million children 
born every year13. The Government is committed to 
achieving full coverage with these vaccines, which 
would double the procurement costs at the current 
prices. In addition, inclusion of hepatitis-B alone in UIP 
would further enhance the total cost of procurement 
by at least two-fold more. Including the DPT-Hep-B-
Hib pentavalent vaccine in the UIP (in place of DPT)
is estimated to cost Rs. 1200 crores14 (Rs. 400 crores 
from the Indian Government and Rs. 800 crores from 
Global Alliance on Vaccine Initiative[GAVI], though 
for a limited period of time). Special vaccination drives 
such as polio involve many fold additional costs15 and 
any improvement in coverage or protection achieved 
through special drives only strengthens the argument 
for similar emphasis and budgetary allocations for 
other UIP vaccines. The secondary vaccines needed 
under various Government programmes could cost 
a few more hundred crores of Rupees. Inclusion of 
vaccines against infections such as rotavirus, mumps, 
measles, rubella (MMR), human papilloma virus 
(HPV), pneumococcal, meningococcal and others 
in any national programme, whether universal or 
selective, will push the total Government procurement 
budget to several thousands of crores of rupees16,17,20, 
even if they are purchased at bulk prices from the 
private sector. The cost may come down significantly 
if they are manufactured in the public sector, but that 
would demand heavy initial investment in technology 
transfer and capacity expansion. Such investments 
may only be justified if the public health needs for 
such vaccines is unequivocally established. Morever, 
the cost of procuring vaccines is only a small fraction 
of the total cost of vaccination/immunization, which 
includes logistics, cold-chain, syringes and other 
accessories, manpower related costs, etc. Even though 
some of these costs may be shared across vaccines, 
there will be an inevitable inflation in the overall costs 
of immunization with every new vaccine added to the 
national programme. While public health necessity can 
justify budgetary increase, proving such a necessity is 
a major challenge16-21, as explained later. Therefore, 
a major policy question is: how much Government 
expenditure on vaccines is adequate to fulfill the public 
health objectives of the Government and the public 
health needs of the people? A related policy question 
is: for those vaccines that are outside the Government 
programmes and left to individual choice, how does 
the Government intend to help the individuals to 
make rational choices on vaccination, unaffected by 
commercial interests and concerns of accessibility and 
affordability?
Vaccine decision support system
 One of the biggest stumbling blocks for 
evidence-based vaccine policy is the lack of reliable 
epidemiological data on disease prevalence and 
incidence, pathogen variations and serotypes/ strains 
and the level of immunity protection against them 
in various populations in India, with and without 
vaccination, or before and after vaccination22-24. The 
current level of disease surveillance is too inadequate 
to support unequivocal scientific decisions based on 
established principles of public health25-27. Studies that 
extrapolate data from small sample sizes based on a few 
hospitals, blood banks etc., from India or from studies 
done abroad only confound the problem further25-
27. These limitations severely affect the task of the 
National Technical Advisory Group on Immunization 
(NTAGI), on which the Union Government currently 
relies for all its vaccination decisions. This situation 
benefits interest groups that attempt to push all available 
vaccines into the National Programmes, regardless 
of their necessity, suitability, cost-efficacy, safety, 
sustainability and health priorities28,29. Unlike curative 
medicines, vaccines are typically given to a large and 
healthy population and this policy therefore needs a 
stronger justification. Once a vaccine is included in the 
National Programme, the manufacturers secure a huge 
market in a single stroke for years together, unlike in 
the case of other medicines10,30. Furthermore, irrational 
vaccine prescriptions and promotion of voluntary 
vaccination by private doctors and aid agencies have 
turned vaccines into consumer goods5,27. Therefore, 
a rational vaccine policy must govern not only the 
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Government’s own vaccination programmes, but also 
enable rational vaccination decisions at all levels 
including private hospitals or individuals in general. 
Hence the need for establishing a rigorous decision 
support system within the purview of the Government 
setup. Since such a system can cater to many public 
health decisions beyond vaccines, such as diagnostics, 
drugs, healthcare delivery systems, outbreak control, 
disaster management etc., it has a stand-alone value 
independent of vaccines, even if it demands huge 
resources.
Vaccine development and production
 It is evident from the literature that strain variation 
of the pathogen and scientific data on sero-prevalence 
are critical for vaccine development, the choice of seed 
strains and production technology29,31-34. Moreover, 
while vaccine development for every pathogenic 
organism may be a legitimate R&D objective, 
researchers benefit from the awareness that every 
vaccine that is worth developing may or may not be 
worth including in the national programme, when 
examined from the public health and policy point of 
view. Thus, prioritization and coordination of national 
vaccine development needs and expenditures are an 
important policy area for the Government. Today, 
there are at least 23 public-funded organizations and 
universities in the country that are engaged in R&D on 
at least 14 new or improved vaccines35. More than 7 
candidate vaccines are being developed and evaluated in 
indigenous Government-funded research organizations, 
while private companies (Shantha Biotech, Bharat 
Biotech, Panacea, Serum Institute of India etc.) are 
developing generic versions of off-patented vaccines 
(Hepatitis B, Influenza type B and their combinations), 
or doing clinical research through international 
collaborations and market contracts. Indigenous 
vaccine R&D capacities (anti-rabies vaccine, typhoid, 
leprosy, Kaysanur forest disease vaccine, JE vaccine, 
new oral cholera vaccine etc.) lie primarily within the 
public funded organizations and public sector units35. 
Therefore, R&D and production in public funded 
organizations, and PSUs must be patronized to develop 
and produce affordable, safe and effective vaccines that 
are needed for the Indian markets or for exports. Prior 
identification of which vaccines are most suitable for 
the public health needs within and outside India may 
be helpful for the researchers in steering their research 
priorities accordingly. Whenever indigenous strains are 
used abroad for developing vaccines or other products, 
whether under collaboration or through independent 
projects, benefit-sharing provisions under the National 
Biodiversity Act must be invoked to maximize the 
access of the fruits of that research for the Indian people 
and Indian manufacturers. 
Vaccine pricing and regulation
 The Government remains the single largest maker 
and buyer of vaccines4, unlike in the case of drugs, 
and therefore has a major stake in determining who 
supplies which vaccines and at what prices for the 
national programmes in the interest of public health. 
All vaccines required for any national (or state) 
programme and procured in bulk by the government can 
be subject to price regulation or exclusively reserved 
for the public sector. The public sector units are most 
suited to ensure consistent manufacture and supply of 
affordable vaccines for national programmes unaffected 
by market vagaries provided they are ensured of 
remunerative prices, Government procurement, prompt 
payments and other advance market commitments. 
The private players can complement the public sector 
in meeting national programmes, while leveraging 
their price competitiveness in other vaccines to cater 
to markets abroad. The Government can facilitate the 
indigenous public and private sector firms to access 
technologies and overseas markets. The Government 
is also responsible to ensure that the PSUs obtain the 
necessary financial, administrative and managerial 
support to comply with good laboratory practices, good 
manufacturing practices and other regulatory norms 
needed for domestic and export markets.
Distribution and utilization of vaccines
 Ultimately, vaccines are useful only if they reach 
people who need them, in good condition, administered 
appropriately and on time. Massive investments have 
taken place over the past decades, and particularly in 
the last few years in strengthening infrastructure and 
building capacities of the healthcare staff related to 
vaccine delivery (http://www.mohfw.nic.in/NRHM/
Documents/Executive_summary_April_09.pdf). Yet, 
large gaps remain in the planning and execution of the 
immunization program in many large states and rural as 
well as urban areas, as is evident from the low coverage 
of primary vaccines under the UIP (http://www.mohfw.
nic.in/NRHM/MIS/MIS%20for%20NRHM%20as%20
on%2030th%20April%202009.xls). This reduces the 
effectiveness of vaccines and masks the true demand 
for vaccines. The problems at the operational level are 
well documented, but attempts to correct them continue 
to be poorly monitored36-44. The ill-effects of the polio 
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eradication campaign on routine immunization have 
been well documented, and illustrate how national 
priorities can easily be diverted45-53. Immunization 
campaigns, particularly because of their repetitive 
nature are not merely technological exercises; they have 
significant social, economic and political dimensions. 
Paying adequate attention to them can ensure better 
acceptability, affordability and sustainability.
National vaccine policy
 In this backdrop, as a part of the broader 
National Health Policy, a national vaccine policy 
is needed, based on the principles of public health 
and comprehensive primary health care. This is to 
enable rational and evidence-based decisions for 
the development, entry, production, stable supply, 
pricing, promotion and use of appropriate vaccines 
on scientific grounds. Additionally, this is also 
needed to protect the national vaccine programmes 
and national health security, as well as to leverage 
indigenous capabilities to cater to domestic and 
overseas markets.
Objectives
To contribute to the prevention of mortality and 1. 
morbidity due to communicable diseases that afflict 
large populations, especially children; through the 
development/production and use of safe, effective 
and affordable vaccines, chosen rationally.
To ensure consistent delivery and administration of 2. 
vaccines to everyone in need.
To achieve national self-reliance in vaccine R&D, 3. 
as well as to maximize the national benefits of 
international sharing of indigenous biological 
diversity of pathogens, hosts and knowledge, to 
the Indian end-users of vaccines on terms that are 
fair and just.
To achieve pre-eminence in the capabilities of the 4. 
indigenous public sector for self reliance and foster 
a leading role for them in all the aspects of vaccine 
development, production and immunization for 
national health security and biosecurity. 
To develop and use the interdisciplinary knowledge 5. 
base needed for science-based policy and evidence-
based medicine in the field of vaccines.
To promote ethical conduct in the development, 6. 
trials, adoption and administration of vaccines, 
especially aimed at children and pregnant 
women.
To develop a system for monitoring and 7. 
compensating adverse events following vaccination 
where required.
To enable India to play a leading role in the 8. 
supply of affordable vaccines to the emerging 
world, considering the declining interest of the 
multinational sector to make cost-effective vaccines 
for the emerging world.
To synergize all other relevant policies for effective 9. 
implementation of the national vaccine policy to 
fulfill the above objectives.
Guiding principles, context and approach:
A vaccine is just one among the many inputs 1. 
needed for effective public health management of 
communicable diseases. Other measures like food 
security, safe drinking water, sanitation, primary 
education, gender sensitivity, and health education 
are known to be the most important factors in the 
control of communicable diseases7,54. Even all the 
known vaccines put together cannot prevent all 
deaths due to all communicable diseases. However, 
amongst medicines, rationally selected vaccines 
are the most cost-effective in reducing morbidity 
and mortality and have an important role to play 
as a public health measure in the control of some 
communicable diseases55-57.
Most of the indigenous capabilities and strengths 2. 
in this area were pioneered or sustained by the 
public sector. Strengthening the role of the public 
sector in the area of vaccines is crucial to ensure 
self-reliance and to protect national health security 
from the uncertainties of the local and global 
market forces, as well as from bio-terrorism and 
biological warfare4,.
Vaccination should be need-based and all vaccines 3. 
are deemed non-universal, unless specified 
otherwise based on scientific evidence4,5,21,25-27. While 
therapeutic vaccines and antisera are administered 
only to patients diagnosed with a treatable 
condition58,59 (e.g., Tetanus, diphtheria anti-snake 
and anti-rabies), preventive vaccines are generally 
administered to largely ‘normal’ populations and 
therefore need stronger medical and economic 
rationale7. Even the so-called ‘Universal’ vaccines 
are universal only for the children and pregnant 
women60,61. Most adult vaccines are not required 
for all the adults, and are often used for “selective” 
immunization of high-risk groups62,63.
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The mere availability of a safe and efficacious or 4. 
even affordable vaccine cannot be a good enough 
justification for its widespread use. Vaccines are 
not consumer goods and should not be given or 
taken, unless their necessity is proven based on the 
scientific principles of public health. As vaccines 
are given to a healthy population, their safety and 
efficacy should be thoroughly assessed based on 
various scientific parameters, before any vaccine is 
introduced into the National Programme.
Vaccines outside the UIP should not be unethically 5. 
promoted through direct or surrogate advertising, 
advocacy by individuals, groups or aid agencies, 
on their own or funded directly or indirectly by the 
vaccine industry64,65.
The choice of which vaccine to give (or 6. 
not to give), target population, and mode of 
administration (dosage, schedule, interval between 
doses, intramuscular or intradermal, etc.), are 
important policy decisions that must be guided by 
a strong scientific rationale, with rigorous inputs 
from multicentric field epidemiology, irrespective 
of whether it has been proven in populations 
abroad66-68. Cost-benefit as well as risk-benefit 
assessment should be carried out in India taking into 
account local serotypes and variations in indigenous 
host-pathogen-environment interactions17-19,28,29. 
These studies can be best done by one or more 
public sector institutions and the results be made 
available openly on the website of the concerned 
agency for wider peer review and public debate. 
The dosage and schedule should also be decided 
after wider scientific debate in the country.
Vaccine choice, source of procurement and the 7. 
quality standards of the products as well as of 
the production system should be based on sound 
principles to achieve maximum benefit to maximum 
number of people and are independent decisions of 
the national Government guided by this national 
policy4 (not imposed by industry and international 
organizations). At the same time, it should be the 
endeavour of this policy to develop all the requisite 
indigenous capabilities in line with the evolving 
global standards, without compromising the 
national health security or self-reliance3, 69.
Technological advances in vaccines, especially 8. 
for mass immunization, have to be measured in 
terms of their improvements in efficacy, long-term 
protection63, safety, and cost-competitiveness, 
stability during storage and transport, and method 
of administration4, 66-71. Technological superiority 
of vaccine should not be assumed solely in terms 
of purity, sophisticated methods of production, 
combinations or other incremental innovations 
aimed at extension of intellectual property and 
commercial monopoly5.
Combination vaccines are convenient but useful 9. 
and acceptable only when universal and non-
universal vaccines are not combined, whether 
for public or private use. In any case, the safety 
and efficacy of every combination vaccine has 
to be freshly established in the target population 
and cannot be extrapolated from the safety and 
efficacy of its individual components5. Cocktail 
combination vaccines and genetically engineered 
multivalent vaccines must be differentiated clearly. 
In case of cocktail combinations, the price of 
the combination may not exceed the sum of its 
individual components. 
Clinical trials and bio-safety regulations in vaccines 10. 
targeting children and pregnant women pose special 
ethical concerns, due to the inability of fetuses and 
infants to decide for themselves, even if the parents 
are assumed to take decisions in the best interest 
of their children71-74. Such issues can become more 
critical when foreign entities conduct clinical 
trials on Indian children. Phase lag is necessary 
in such situations74. In addition, unless absolutely 
necessary, vaccine trials in children should begin 
with grown up children and then move downwards. 
Suitable amendments may be introduced in the 
proposed National Biotechnology Authority Act to 
address these and other public health concerns. 
The Government shall evolve a suitable legislation 11. 
enabling Adverse Vaccine Reaction Monitoring & 
compensation for injuries to any person(s) arising 
out of vaccinations in India, including for those in 
the trial phase75,76. This should apply to all vaccines, 
whether provided by the Government, public sector 
or by the private manufacturers/practitioners. The 
legislation would be designed to fix responsibility 
and deliver compensation adequately and promptly 
in the event of injuries/adverse events due to 
vaccines and vaccination77. 
Pricing of all vaccines should be brought under the 12. 
Drug Price Control Order (DPCO) and subjected 
to regulation in accordance with the objectives of 
this policy78,79. Pricing of vaccines should be done 
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on a transparent basis and agreed principles of 
reasonable returns on investment, rates of royalty 
and costing of R&D efforts. There should be no 
overhead taxes imposed on vaccines such as excise 
duty, value added tax (VAT), customs duty etc. The 
difference between maximum retail price (MRP) 
and the price at which vaccines are supplied to 
wholesalers, retailers, hospitals or even to doctors 
will also be minimized to deter monetary incentives 
for unethical vaccine promotions80.
International sharing of indigenous biological 13. 
diversity of pathogens, hosts81 and knowledge 
should be governed by the legal principles of prior 
informed consent and benefits sharing agreements 
set in the National Bio-Diversity Act. The 
material transfer agreement should have a clause 
preventing the recipient from seeking or claiming 
intellectual property rights over any inventions 
derived from Indian biodiversity or indigenous 
knowledge. It should also have copyleft style 
clauses for open sharing of the research results 
to develop vaccines and other technologies to 
combat diseases. Prior informed consent to any 
overseas individual or entity should be subject to 
the condition that Indian scientists, technologists 
and public sector manufacturing entities will 
have automatic royalty-free rights to use all the 
further improvement in that knowledge and any 
technology, product or process that comes out of 
the shared biological resource or knowledge, or 
to license it further to indigenous private firms if 
deemed necessary. This maximizes the national 
benefits of international sharing to the Indian end-
users of vaccines 
Publicly funded R&D on vaccine technologies 14. 
should be made available widely on a non-
exclusive basis to promote manufacture of quality 
vaccines at competitive prices. Research papers 
emerging out of publicly funded R&D should also 
be made available freely through an open access 
policy. In all publicly funded vaccine research 
and development programmes, affordable access 
to vaccine technologies and the crucial role of the 
public sector manufacture for national programmes 
should be given priority over all IPR issues and 
other technology transfer considerations3. Further, 
knowledge commons approach to R&D and 
other measures that enhance access to vaccine 
technologies identified under the National Vaccine 
Policy should be promoted. 
The above principles and public health concerns 15. 
of the nation will have an overriding priority 
over any multilateral, bilateral or regional trade 
agreements.
Policy measures
The success of vaccination or any other public health 1. 
program depends heavily on the disease surveillance 
and monitoring system in the country4. Ideally, 
such a system should contain frequently collected 
information on the incidence and prevalence of 
diseases in the population, local variations in the 
pathogens including serotypes, resistance to drugs/
antibiotics if any, host response to vaccination82, 
efficacy83 and duration of protection63, etc. These 
data form the basis for all decisions regarding 
whether to adopt vaccination as a strategy and if 
so, whether universal or selective and for how 
long84, 25. In order to augment the present mechanisms 
available for disease surveillance and monitoring as 
well as vaccination, the Panchayati Raj institutions 
should be strengthened, and training imparted to the 
health management information system (HMIS), 
integrated disease surveillance project (IDSP), 
Accredited social health activist (ASHA), Auxiliary 
Nurse Midwife (ANM) and health workers.
To ensure selection of appropriate vaccines on 2. 
scientific grounds, for the Universal Immunization 
Programme, well-defined criteria of cost-efficacy 
and logistical feasibility37-44, appropriateness 
should be formed based on the science of Public 
Health17-19,28,29. A Committee should do this 
selection after a broad based debate amongst the 
concerned Public Health experts. No new vaccine 
should be introduced into the UIP unless adequate 
and sustained resources/efforts have been devoted 
to achieve universal coverage of the existing 
vaccines3. The lure of external aid/loan cannot be a 
sufficient ground for introduction of new vaccines 
under UIP4, 19, 28.
In order to ensure stable and affordable supply of 3. 
vaccines to the national immunization programme 
and also to address national health security 
and biosecurity concerns, all essential vaccines 
covered under UIP (TT, DT, DTP, BCG, Polio, 
Measles) must continue to be produced by the 
public sector71. Further, the presence of at least 
two functional PSUs per vaccine (as a backup for 
each other) must be ensured as a protection against 
market uncertainties.
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For patented vaccines and other interventions 4. 
needed for public health, the Government should 
take all necessary law and policy measures 
including government use and compulsory license 
provisions to ensure timely availability of vaccines 
at an affordable cost. For off-patented vaccines, 
suitable law and policy measures should be taken 
to promote competition by providing incentives to 
generic manufacturers.
All the vaccine PSUs must be urgently revived and 5. 
modernized to fill the demand-supply gaps in all 
essential vaccines and anti-sera, including the UIP 
vaccines13, 3, 85. The Government purchase orders 
for safe & effective vaccines available from PSUs 
must not be diverted to the private sector under any 
pretext3, 71. For example, the recent introduction of 
a pentavalent vaccine (that combines DTP with 
Hepatitis B and Influenza type B) into the UIP14 
effectively diverts all the DTP purchase order 
from PSUs to private entities, as the PSUs do 
not manufacture them so far. Besides, the merits 
of universal vaccination against Hepatitis B and 
Influenza type B are highly debatable11, 21, 25, 29, 86, 87.
Various vaccine PSUs are currently under different 6. 
managerial regimes – state and central Governments, 
and even within the central Government, under 
ministry of health and family welfare (MOHFW), 
department of biotechnology (DBT) and national 
dairy development board (NDDB)3. In order to 
enhance functional coordination between them to 
meet the national vaccine needs, their governing 
bodies should be expanded to include public 
health experts, epidemiologists, microbiologists 
immunologists, vaccine policy experts, 
pharmacologists, economists, sociologists and other 
interdisciplinary experts and non-Governmental 
organizations (NGOs).
The current National Technical Advisory Group on 7. 
Immunization (NTAGI) should be restructured into 
a central National Vaccine Regulatory Authority 
(NVRA) that allows wider representation to 
indigenous scientists, policy experts and indigenous 
public sector and civil society. Apart from invited 
membership, provision should also be made for 
voluntary participation of representatives from any 
non-commercial organization. This authority would 
be empowered to take all major decisions such as 
monitoring disease burden, vaccine development, 
adoption, production, procurement, distribution, 
immunization and follow-up. 
Indigenous vaccine R&D and production 8. 
capacities must be strengthened to ensure a stable 
and affordable supply of all essential vaccines, 
especially the UIP vaccines3. For this purpose, 
the core strengths of the vaccine PSUs must be 
preserved and nurtured71 with higher functional 
autonomy (at least at par with the Navratnas), 
incentives to attract interdisciplinary talent for 
R&D and production. 
Enhanced public funding and programme support 9. 
for R&D into communicable diseases, especially 
neglected diseases and vaccine-preventable diseases.
Further strengthening the integrated disease 10. 
surveillance programme. Critical appraisal of 
literature should be undertaken while considering 
new vaccine adoption in UI or SI decisions. Limited 
data on the actual prevalence of a disease may over-
estimate the actual disease burden. Large multicentre 
and community based studies should confirm the 
real burden of any particular disease in the country. 
Improved logistics and supply chain system, 11. 
including maintenance of cold-chain during 
periods of heavy load shedding, especially 
in rural areas. Emphasis on the outreach of 
vaccination programmes to remote areas and the 
marginalized populations, tribals etc; Promotion 
of awareness and trust building in communities 
through various measures to ensure full 
vaccination coverage.
Regulation of advertisements and other 12. 
promotional marketing activities to prevent 
unethical means and kickbacks to doctors. 
Literature should not be cited selectively to 
base decisions. The role of the industry as the 
educators of the professionals, policy makers and 
people must be discouraged. Direct-to-consumer 
promotional advertisements64,65 on upcoming 
vaccines (e.g., rotavirus, HPV, Chickenpox etc.) 
with incomplete and biased information must be 
banned.
Government procurement of vaccines under UIP 13. 
must be based on price and opportunity parity, and no 
PSU should be excluded from Government vaccine 
procurement, as long as the product quality and 
affordable price are ensured3, 71. Similarly, no PSUs 
should be excluded from producing any vaccine, 
as long as it stakes a credible claim to manufacture 
it in compliance with all the regulatory and quality 
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norms at competitive prices. The Government may 
make advance market commitments with vaccine 
PSUs subject to quality parameters, but not with 
any other private or foreign entity to the detriment 
of the vaccine PSU. No private firm should be 
paid higher prices than their PSU counterparts 
supplying to UIP. The whole process should be 
made transparent.
Any private sector unit that wishes to produce 14. 
new (non-UIP) or combination vaccines must 
produce some UIP vaccines (individually and 
not as combinations) to fill any shortfalls in PSU 
production and Government procurement5.
A critical review of the current UIP vaccines and 15. 
new vaccines may be undertaken by the National 
Vaccine Regulatory Authority (NVRA). Any new 
vaccine introduction in UIP must be qualified 
before its introduction for Universal or Selective 
Immunization, based on epidemiological evidence, 
suitability and efficacy to the local pathogens and 
human populations, risk-benefit and cost-benefit 
analyses3-5, 7, 25, 29, 31, 63, 65, 73, 81-83, 87, 88.
Similarly, a critical review of the combination of 16. 
UIP and non-UIP vaccines must be carried out in 
view of the stated policy objectives. Combining 
any UIP vaccine with any non-UIP vaccine 
needs rigorous scrutiny and public debate. Other 
combinations must be proven to be equivalent 
to or more effective and safer than single 
vaccines before adoption. In any case, cocktail 
combinations and multivalent vaccines must be 
clearly differentiated5.
The Government of India is solely responsible for 17. 
the compliance of its PSUs for good manufacturing 
practice (GMP) and all other regulatory norms, 
as well as to prevent stoppage of production on 
such counts89. Therefore, the Government of India 
must provide all the necessary administrative 
and financial support for PSU compliance with 
GMP and all other regulations3. The governing 
bodies and other technical committees of PSUs 
must be expanded to enable expert monitoring/
advice from vaccine policy and public health 
experts, apart from scientists/technologists of 
relevance. Representatives from private vaccine 
manufacturers and industry-funded medical 
associations/academies must be specifically 
prohibited to prevent conflicts of interest. 
In order to make the essential vaccines more 18. 
affordable to the indigenous end-consumers, 
measures such as tax concessions/exemptions may 
be considered.
Rejuvenation of the existing institutions of research, 19. 
education and training of public health workers. 
The National Vaccine Regulatory Authority 
(NVRI) will identify such aspects relevant to 
India and coordinate with existing agencies like 
Indian Council of Medical Research (ICMR), 
DBT, Council of Scientific and Industrial Research 
(CSIR) etc. 
Promotion of health systems research to formulate 20. 
optimized health systems that can deliver vaccines 
efficiently and effectively.
Strengthening of basic infrastructure and manpower 21. 
in primary health care centers (PHC) and ancillary 
programs such as ICDS and the ASHA network, 
with emphasis on name-based tracking of 
individual children and women, ensuring planned 
fixed-day immunization sessions, reporting 
based on correct denominators and frequent 
decentralized monitoring of coverage independent 
of service reports are keystones of successful 
coverage7,37,39,41,44. In addition, the regular audit of 
vaccine utilization is essential. Currently, all these 
are not subject to regular and independent scrutiny, 
and can be brought under the ambit of NVRA. 
A prevailing concern has been the tendency of 
immunization programs to operate independently 
of other primary health care programs7. Maintaining 
this balance will be critical to the success of both, 
the UIP and the other PHC programs.
Increase in budgetary allocations for investment in 22. 
proven cost-effective programmes.
Private vaccine markets and also their use in private 23. 
clinics should be regulated through a mechanism 
to be brought under National Vaccine Regulatory 
Authority (NVRA) supervision. 
A thorough and transparent review of all public 24. 
private partnerships (PPP) in vaccine development, 
production and delivery is needed, including the 
upcoming vaccine park at Chengalpattu3,13. All 
measures should be taken to ensure that PPPs 
do not amount to public spending and private 
profiteering. The public private partnerships for 
developing and manufacturing new vaccines may 
be beneficial only when the state of art for making 
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vaccines remains with public sector, while private 
sector is made to meet vaccines that are needed.
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